Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia.

QJM. 1999 Aug;92(8):433-41. Unique Identifier : AIDSLINE MED/20093329
Bjoro K; Skaug K; Haaland T; Froland SS; Department of Medicine, National Hospital, Oslo, Norway.

Abstract: The clinical course of HCV infection in patients with primary hypogammaglobulinaemia appears to be more severe than in immunocompetent patients. We studied the long-term course of chronic HCV infection in 20 Norwegian hypogammaglobulinaemia patients with a 13-15 year known history of HCV infection. Twelve of 20 patients developed cirrhosis during the observation period (1984-1999), and the remaining eight also had chronic liver disease verified by liver biopsy in the majority of the cases. Eleven of the 20 patients are dead. Two died following liver transplantation for HCV cirrhosis. Five died due to terminal liver failure without receiving a liver allograft. Two patients died from other causes, but with advanced liver disease contributing to the outcome, while two deaths were unrelated to the HCV infection. Among patients with common variable immunodeficiency (CVI), five out of six are dead. Two patients cleared the hepatitis C virus 3 years following interferon monotherapy, while three patients achieved a sustained response to combination therapy with interferon and ribavirin. Viral load did not seem to have a major impact on disease progression. Our results emphasize the severity of hepatitis C virus infection in patients with hypogammaglobulinaemia. Patients with CVI appear to have the poorest prognosis.

Keywords: JOURNAL ARTICLE Adolescence Adult Agammaglobulinemia/IMMUNOLOGY/*VIROLOGY Antiviral Agents/THERAPEUTIC USE Common Variable Immunodeficiency/MORTALITY Disease Progression Female Follow-Up Studies Hepatitis C, Chronic/*COMPLICATIONS/DRUG THERAPY/IMMUNOLOGY Human Interferons/THERAPEUTIC USE Liver Cirrhosis/*ETIOLOGY Liver Transplantation/MORTALITY Male Middle Age Ribavirin/THERAPEUTIC USE

KWDjournalarticleadolescenceadultagammaglobulinemia/immunology/KWDvirologyantiviralagents/therapeuticusecommonvariableimmunodeficiency/mortalitydiseaseprogressionfemalefollow-upstudieshepatitisc,chronic/KWDcomplications/drugtherapy/immunologyhumaninterferons/therapeuticuselivercirrhosis/KWDetiologylivertransplantation/mortalitymalemiddleageribavirin/therapeuticuse
000430
A0040913

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .